This trial is designed to compare the efficacy and safety of two diabetes treatments, Gla-300 and IDeg-100, in insulin-naïve patients with Type 2 Diabetes Mellitus and renal impairment. The hypothesis is that Gla-300 is non-inferior to IDeg-100 in terms of glucose control. If achieved, the trial will also test for the superiority of Gla-300 compared with IDeg-100 in terms of reducing Hemoglobin A1c levels, without an increased potential risk of hypoglycemia.
1 Primary · 9 Secondary · Reporting Duration: Baseline to end of study (25 weeks)
630 Total Participants · 2 Treatment Groups
Primary Treatment: Gla-300 arm · No Placebo Group · Phase 4
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: